MétaCan
Menu
Back to cohort
Record W2587136693 · doi:10.1093/ecco-jcc/jjx002.734

P610 Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study

2017· article· en· W2587136693 on OpenAlexaff
Séverine Vermeire, Walter Reinisch, Dorota Waśko−Czopnik, Tim Van Kaem, Julie Desrivot, Frédéric Vanhoutte, Johan Beetens

Bibliographic record

VenueJournal of Crohn s and Colitis · 2017
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsMcMaster University
Fundersnot available
KeywordsGastroenterologyMedicinePlaceboMyeloperoxidaseInternal medicineCalprotectinUlcerative colitisRandomizationClinical endpointColitisInflammatory bowel diseaseClinical trialInflammationPathologyDisease

Abstract

fetched live from OpenAlex

Background: GPR84, a GPCR activated by medium-chain free fatty acids, is primarily expressed on white blood cells (polymorphonuclear, monocyte/macrophage). GLPG1205 is a potent and selective antagonist of GPR84, inhibiting GPR84-induced neutrophil migration in vitro. In a mouse IBD model (DSS), GLPG1205 dose-dependently decreased disease activity, histological activity, neutrophil influx as well as colonic MPO content. Methods: The efficacy and safety of GLPG1205 in moderate-to-severe UC (Mayo score 6–12 with an endoscopic subcore of ≥2) was evaluated in an exploratory, double-blind study, in 63 patients (aged 18–75) treated for 12 weeks with 100 mg q.d. GLPG1205 or placebo (pbo) in a 2:1 randomization (NCT02337608). A stable background of 5-aminosalicylates, immunosuppressants or steroids was allowed. Mayo scores and biopsies for Geboes scores and myeloperoxidase (MPO) positive cells (immunohistochemistry) were collected at baseline (BL) and week 8. Fecal calprotectin (FC), subscores for partial Mayo and PK were evaluated at BL and week 4, 8 and 12. Results: Baseline characteristics, including duration of disease (6.9 y), prior and concomitant medication, Mayo score, FC, MPO positive cells were similar in both groups. At primary endpoint (W8), there was no statistically significant difference in Mayo score, Mayo clinical response, clinical remission, mucosal healing, Geboes Index, and histological response (MPO) between GLPG1205 and placebo (see table). Over the total 12-week treatment period, no treatment difference was observed in the partial Mayo score, the Mayo sub-scores or FC changes. GLPG1205 was well tolerated. Worsening of colitis, leading to study discontinuation, was reported by 4 patients (3 GLPG1205, 1 placebo). Patients showed a good drug exposure with average plasma concentrations within the range of exposures observed in healthy subjects. 1Decrease in Mayo score ≥3 points and ≥30% and a decrease in rectal bleeding ≥1 or an absolute score 0/1. 2Mayo score ≤2 and no individual subscore >1. 3Endoscopy subscore 0 or 1. BL = baseline. Conclusions: In this 12-week first-in-patient study with a GPR84 antagonist in patients with moderate to severe UC, GLPG1205 was well-tolerated. Compared to placebo, GLPG1205 had no effect on the clinical parameters or on the biomarkers related to the mode of action (FC or MPO). Therefore, our data suggest that inhibition of GPR84-mediated processes on inflammatory cells may not be relevant in the pathophysiology of active UC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0020.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.277
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicInflammatory Bowel DiseaseFrench-language works237,207